SCHEMBL8749474

SCHEMBL8749474

CC(Cl)OS(=O)(=O)OCl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14685976 0.72
SCHEMBL18919380 0.72 CA1 (0.39)
SCHEMBL2734238 0.71
SCHEMBL847661 0.71
SCHEMBL11791947 0.69 LMNA (0.46)
SCHEMBL27786735 0.69
SCHEMBL541873 0.67
SCHEMBL8666161 0.67
SCHEMBL701817 0.65 TSHR (0.40)
SCHEMBL29155217 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260124190-A1 METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF RIGEL PHARMACEUTICALS, INC. (US) 2026-05-07 US disclosed
US-12441723-B2 Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations RIGEL PHARMACEUTICALS, INC. (US) 2025-10-14 US disclosed
US-12357623-B2 Method for treating a disease or condition using a pyrazole compound or formulation thereof RIGEL PHARMACEUTICALS, INC. (US) 2025-07-15 US disclosed
US-20240382470-A1 Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus RIGEL PHARMACEUTICALS INC (US) 2024-11-21 US disclosed
CN-118510771-A IRAK inhibitors for the treatment of conditions associated with cytokine release associated with respiratory viral infection 里格尔药品股份有限公司 2024-08-16 CN disclosed
EP-4399208-A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS Rigel Pharmaceuticals, Inc. (US) 2024-07-17 EP disclosed
US-20230399326-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS RIGEL PHARMACEUTICALS, INC. (US) 2023-12-14 US disclosed
WO-2023038815-A1 IRAK INHIBITOR FOR TREATING CYTOKINE RELEASE-RELATED CONDITIONS ASSOCIATED WITH INFECTION BY A RESPIRATORY VIRUS RIGEL PHARMACEUTICALS, INC. (US) 2023-03-16 WO disclosed
US-20220306620-A1 PYRAZOLE COMPOUNDS, FORMULATIONS THEREOF, AND A METHOD FOR USING THE COMPOUNDS AND/OR FORMULATIONS RIGEL PHARMACEUTICALS, INC. (US) 2022-09-29 US disclosed
US-11447449-B2 Inhibitors of indoleamine 2,3-dioxygenase and methods of their use BRISTOL-MYERS SQUIBB COMPANY (US) 2022-09-20 US disclosed
EP-0577725-A4 TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES UNIV FLORIDA (US) 1996-04-17 EP disclosed
US-5413996-A Delivery of steroid sex hormone or antiinflammatory steroid to the brain UNIVERSITY OF FLORIDA (US) 1995-05-09 US disclosed
US-RE34865-E Antibiotics HOECHST AKTIENGESELLSCHAFT (DE) 1995-02-21 US disclosed
EP-0577725-A1 TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES UNIVERSITY OF FLORIDA (US) 1994-01-12 EP disclosed
EP-0539493-A4 TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES 1993-06-02 EP disclosed
EP-0539493-A1 TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES. BODOR NICHOLAS S (US) 1993-05-05 EP disclosed
US-5177064-A TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES UNIVERSITY OF FLORIDA (US) 1993-01-05 US disclosed
WO-1992017185-A1 TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES UNIVERSITY OF FLORIDA (US) 1992-10-15 WO disclosed
US-5100887-A Bactericides HOECHST AKTIENGESELLSCHAFT (DE) 1992-03-31 US disclosed
WO-1992000988-A1 TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES BODOR NICHOLAS S (US) 1992-01-23 WO disclosed